Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Serum insulin-like factor 3 quantification by LC-MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pubertal development in 46,XY patients with NR5A1 mutations

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. CPMS-improving patient care in Europe via virtual case discussions

    Research output: Contribution to journalReviewResearchpeer-review

  3. ENDO-ERN expert opinion on the differential diagnosis of pubertal delay

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dynamic changes of reproductive hormones in male minipuberty: Temporal dissociation of Leydig- and Sertoli-cell activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Oophorectomy and rate of dementia: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Insulin-like factor 3 (INSL3) is an emerging testicular marker, yet larger studies elucidating the clinical role of INSL3 in patients with hypogonadism are lacking. The aim was to describe serum INSL3 concentrations analyzed by LC-MS/MS methodology in males with hypogonadotropic hypogonadism (HH) and Klinefelter syndrome (KS).

METHODS: This was a combined study from two tertiary centers in Denmark and France analyzing INSL3 concentrations by LC-MS/MS. In total, 103 patients with HH and 82 patients with KS were grouped into treated (HH: n = 96; KS: n = 71) or untreated (HH: n = 7; KS: n = 11). Treatment modalities included testosterone and hCG. Serum concentrations and standard deviation (SD) scores of INSL3, total testosterone, and LH according to age and treatment were evaluated.

RESULTS: In both HH and KS, INSL3 concentrations were low. In HH, INSL3 was low regardless of treatment, except for some hCG-treated patients with normal concentrations. In untreated HH, testosterone was low, while normal to high in most testosterone- and hCG-treated patients. In untreated KS, INSL3 and testosterone concentrations were low to normal, while in testosterone-treated KS, serum INSL3 was low in most patients. INSL3 SD scores were significantly lower in untreated HH than in untreated KS (p = 0.01).

CONCLUSIONS: The dichotomy between lower INSL3 and higher testosterone concentrations, particularly observed in hCG-treated patients with HH, confirms that INSL3 is a different marker of Leydig cell function than testosterone. However, the clinical application of INSL3 in males with hypogonadism remains unclear.

Original languageEnglish
JournalEndocrine
Volume71
Issue number3
Pages (from-to)578-585
Number of pages8
ISSN1355-008X
DOIs
Publication statusPublished - Mar 2021

    Research areas

  • Hypogonadotropic hypogonadism, INSL3, Klinefelter syndrome, LC–MS/MS

ID: 61923297